Nanobiotix is a clinical-stage biotechnology company developing physics-based nanoparticle therapies for cancer treatment and neurological diseases. Its most advanced product, JNJ-1900 (NBTXR3), is a first-in-class nanoradioenhancer consisting of hafnium oxide nanoparticles administered via intratumoral injection to enhance the tumor-killing effects of radiotherapy across solid tumors; the company has licensed this therapy to Johnson & Johnson under a global development and commercialization agreement. The company generates revenue through milestone payments and royalties on net sales from its J&J partnership, as well as separate licensing agreements in Asia and research funding from academic collaborators, while maintaining preclinical and discovery-stage platforms targeting hepatic clearance and neurological indications.